Neurocrine Biosciences (NBIX) FCF Margin (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported FCF Margin for 16 consecutive years, with 13.41% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, FCF Margin rose 39.0% year-over-year to 13.41%; the trailing twelve-month figure through Jun 2026 stood at 25.8% (up 473.0% YoY), and the FY2025 full-year result was 26.17%, up 252.0% from the prior year.
• FCF Margin eased to 13.41% in Q2 2026 per NBIX's latest filing, from 16.78% in the prior quarter.
• Across five years, FCF Margin topped out at 48.52% in Q4 2025 and bottomed at 31.8% in Q1 2023.
• Historically, FCF Margin has averaged 20.61% across 5 years, with a median of 23.6% in 2024.
• The sharpest annual moves came in 2022 and 2024: FCF Margin sank 5048 bps in 2022, then jumped 5492 bps in 2024.
• Over 5 years, FCF Margin stood at 34.27% in 2022, then plunged by 33 bps to 22.92% in 2023, then jumped by 63 bps to 37.47% in 2024, then increased by 29 bps to 48.52% in 2025, then sank by 72 bps to 13.41% in 2026.
• According to Business Quant data, FCF Margin over the past three periods registered 13.41%, 16.78%, and 48.52% for Q2 2026, Q1 2026, and Q4 2025 respectively.